Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach

Khaghanzadeh,Narges; Nakamura,Kazuyuki; Kuramitsu,Yasuhiro; Ghaderi,Abbas; Mojtahedi,Zahra

doi:10.3892/ol.2016.5352

Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach

Authors:
- Narges Khaghanzadeh
- Kazuyuki Nakamura
- Yasuhiro Kuramitsu
- Abbas Ghaderi
- Zahra Mojtahedi
View Affiliations

Affiliations: Department of Immunology, Hormozgan University of Medical Sciences, Bandar Abbas 79196, Iran, Department of Biochemistry and Functional Proteomics, Yamaguchi University, Graduate School of Medicine, Yamaguchi 7538511, Japan, Cancer Biomarkers and Proteomics Lab, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz 71348, Iran
Published online on: November 4, 2016 https://doi.org/10.3892/ol.2016.5352
Pages: 5295-5302

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Umbelliprenin (Umb), a natural coumarin, has demonstrated anti-tumor activities, both in vitro and particularly in vivo, in several types of cancer, including lung cancer. The present study aimed to identify molecular targets of Umb using a high-throughput approach. Lung cancer cell lines, QU‑DB (large‑cell lung carcinoma) and A549 (adenocarcinoma), were treated with Umb. Differentially‑expressed proteins were identified using two‑dimensional electrophoresis coupled to mass spectrometry. In the QU‑DB cells, differential expression of proteins, including downregulation of the tumorigenic protein heat shock protein 90 kDa and upregulation of the potential anti‑tumor proteins Nipsnap1 and glycine‑tRNA ligase (GRS), suggested that Umb is a strong anti‑tumor compound. In the A549 cells, differential expression of proteins indicated possible contradictory effects of Umbregarding tumorigenesis, which included downregulation of the tumorigenic protein cyclophilin and the tumor suppressor MST, and upregulation of stathmin (tumorigenic) and calreticulin. Calreticulun, in addition to GRS in QU‑DB cells, stimulates anti‑tumor immune responses in vivo. To the best of our knowledge, the present study is the first to use a high‑throughput approach to identify targets of Umb in cancer. These molecular targets suggested that Umb may exhibit stronger in vitro anti‑tumor activity against the large‑cell carcinoma model than the adenocarcinoma model. Furthermore, it has been reported that Umb exhibits higher cytotoxicity against QU‑DB cells than A549 cells in vitro, and significant Umb anti-tumor activity against lung cancer in vivo, which is consistent with previously published literature. In each cell type, immune‑associated molecules were upregulated, indicating that this naturally occurring compound exhibits marked anti-tumor activity in vivo. However, further studies that investigate the effect of Umb in different in vitro models of cancer are required.

View Figures

View References

1	Lacy A and O'Kennedy R: Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des. 10:3797–3811. 2004. View Article : Google Scholar : PubMed/NCBI
2	Khaghanzadeh N, Mojtahedi Z, Ramezani M, Erfani N and Ghaderi A: Umbelliprenin is cytotoxic against QU-DB large cell lung cancer cell line but anti-proliferative against A549 adenocarcinoma cells. DARU. 20:692012. View Article : Google Scholar : PubMed/NCBI
3	Iranshahi M, Askari M, Sahebkar A and Hadjipavlou-Litina D: Evaluation of antioxidant, anti-inflammatory and lipoxygenase inhibitory activities of the prenylated coumarin umbelliprenin. DARU. 17:99–103. 2009.
4	Soltani F, Mosaffa F, Iranshahi M, Karimi G, Malekaneh M, Haghighi F and Behravan J: Auraptene from Ferula szowitsiana protects human peripheral lymphocytes against oxidative stress. Phytother Res. 24:85–89. 2010. View Article : Google Scholar : PubMed/NCBI
5	Shahverdi AR, Saadat F, Khorramizadeh MR, Iranshahi M and Khoshayand MR: Two matrix metalloproteinases inhibitors from Ferula persica var. persica. Phytomedicine. 13:712–717. 2006. View Article : Google Scholar : PubMed/NCBI
6	Soltani F, Mosaffa F, Iranshahi M, Karimi G, Malekaneh M, Haghighi F and Behravan J: Evaluation of antigenotoxicity effects of umbelliprenin on human peripheral lymphocytes exposed to oxidative stress. Cell Biol Toxicol. 25:291–296. 2009. View Article : Google Scholar : PubMed/NCBI
7	Khaghanzadeh N, Samiei A, Ramezani M, Mojtahedi Z, Hosseinzadeh M and Ghaderi A: Umbelliprenin induced production of IFN-γ and TNF-α, and reduced IL-10, IL-4, Foxp3 and TGF-β in a mouse model of lung cancer. Immunopharmacol Immunotoxicol. 36:25–32. 2014. View Article : Google Scholar : PubMed/NCBI
8	Iranshahi M, Sahebkar A, Takasaki M, Konoshima T and Tokuda H: Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo. Eur J Cancer Prev. 18:412–415. 2009. View Article : Google Scholar : PubMed/NCBI
9	Barthomeuf C, Lim S, Iranshahi M and Chollet P: Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine. 15:103–111. 2008. View Article : Google Scholar : PubMed/NCBI
10	Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J and Zureik M: 4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index. Lancet Oncol. 7:829–836. 2006. View Article : Google Scholar : PubMed/NCBI
11	Hamidinia M, Ramezani M and Mojtahedi Z: Cytotoxic/proliferative effects of umbelliprenin on colon cancer cell lines. Ann Colorectal Res. 1:101–105. 2013. View Article : Google Scholar
12	Cai XZ, Huang WY, Qiao Y, Du SY, Chen Y, Chen D, Yu S, Che RC, Liu N and Jiang Y: Inhibitory effects of curcumin on gastric cancer cells: A proteomic study of molecular targets. Phytomedicine. 20:495–505. 2013. View Article : Google Scholar : PubMed/NCBI
13	Askari M, Sahebkar A and Iranshahi M: Synthesis and purification of 7-prenyloxycoumarins and herniarin as bioactivenatural coumarins. Iran J Basic Med Sci. 12:63–69. 2009.
14	Mojtahedi Z, Safaei A, Yousefi Z and Ghaderi A: Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS. 15:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
15	Okutucu B, Dinçer A, Habib O and Zihnioglu F: Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods. 70:709–711. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sarvari J, Mojtahedi Z, Kuramitsu Y, Malek-Hosseini SA, Shahrabadi M Shamsi, Ghaderi A and Nakamura K: Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection. Oncol Lett. 2:871–877. 2011.PubMed/NCBI
17	Wang Q, An L, Chen Y and Yue S: Expression of endoplasmic reticulum molecular chaperon GRP94 in human lung cancer tissues and its clinical significance. Chin Med J (Engl). 115:1615–1619. 2002.PubMed/NCBI
18	Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, et al: Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. Curr Mol Med. 12:1125–1141. 2012. View Article : Google Scholar : PubMed/NCBI
19	Byun Y, Chen F, Chang R, Trivedi M, Green KJ and Cryns VL: Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ. 8:443–450. 2001. View Article : Google Scholar : PubMed/NCBI
20	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target in cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
21	Cheng CW, Kuo CY, Fan CC, Fang WC, Jiang SS, Lo YK, Wang TY, Kao MC and Lee AY: Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species. Cell Death Dis. 4:e6812013. View Article : Google Scholar : PubMed/NCBI
22	Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, et al: Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 9:548–556. 2013. View Article : Google Scholar : PubMed/NCBI
23	Christiansen A and Dyrskjøt L: The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancer. Cancer Lett. 331:18–23. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kim SN, Kim NH, Park YS, Kim H, Lee S, Wang Q and Kim YK: 7-Diethylamino-3(2′-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells. Biochem Pharmacol. 77:1773–1779. 2009. View Article : Google Scholar : PubMed/NCBI
25	Lawrenson K, Mhawech-Fauceglia P, Worthington J, Spindler TJ, O'Brien D, Lee JM, Spain G, Sharifian M, Wang G, Darcy KM, et al: Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis. Int J Cancer. 137:1806–1817. 2015. View Article : Google Scholar : PubMed/NCBI
26	Kim Y, Jang M, Lim S, Won H, Yoon KS, Park JH, Kim HJ, Kim BH, Park WS, Ha J and Kim SS: Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. Hepatology. 54:1661–1678. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kamal MA and Christopherson RI: Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates. Int J Biochem Cell Biol. 36:545–551. 2004. View Article : Google Scholar : PubMed/NCBI
28	Burke AJ, Sullivan FJ, Giles FJ and Glynn SA: The Yin and Yang of nitric oxide in cancer progression. Carcinogenesis. 34:503–512. 2013. View Article : Google Scholar : PubMed/NCBI
29	Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE and Saatcioglu F: The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res. 68:9255–9264. 2008. View Article : Google Scholar : PubMed/NCBI
30	Rawat SJ and Chernoff J: Regulation of mammalian Ste20 (Mst) kinases. Trends Biochem Sci. 40:149–156. 2015. View Article : Google Scholar : PubMed/NCBI
31	Malhotra A, Shibata Y, Hall IM and Dutta A: Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes. Cancer Biol Ther. 14:840–852. 2013. View Article : Google Scholar : PubMed/NCBI
32	Park MC, Kang T, Jin D, Han JM, Kim SB, Park YJ, Cho K, Park YW, Guo M, He W, et al: Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. Proc Natl Acad Sci USA. 109:E640–E647. 2012. View Article : Google Scholar : PubMed/NCBI
33	Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA and Patierno SR: Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat. 59:15–26. 2000. View Article : Google Scholar : PubMed/NCBI
34	Horie M, Saito A, Mikami Y, Ohshima M, Morishita Y, Nakajima J, Kohyama T and Nagase T: Characterization of human lung cancer-associated fibroblasts in three-dimensional in vitro co-culture model. Biochem Biophys Res Commun. 423:158–163. 2012. View Article : Google Scholar : PubMed/NCBI
35	Yousefi Z, Sarvari J, Nakamura K, Kuramitsu Y, Ghaderi A and Mojtahedi Z: Secretomic analysis of large cell lung cancer cell lines using two-dimensional gel electrophoresis coupled to mass spectrometry. Folia Histochem Cytobiol. 50:368–874. 2012. View Article : Google Scholar : PubMed/NCBI
36	Korbelik M, Zhang W and Merchant S: Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: Surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother. 60:1431–1437. 2011. View Article : Google Scholar : PubMed/NCBI
37	Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, Li Y, Liu Z, Dong Y, Chen L and Jin B: Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother. 61:855–864. 2012. View Article : Google Scholar : PubMed/NCBI